InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.93
(
0.25%
)
US TECH 100
19,344.00
(
-0.36%
)
Dow Jones
42,208.22
(
0.20%
)
Brent Oil
74.56
(
-0.01%
)
Bitcoin
63,715.21
(
-0.86%
)
Post# of 253213
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120491
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 208184

Wednesday, 03/29/2017 11:13:47 AM

Wednesday, March 29, 2017 11:13:47 AM

Post# of 253213
FDA approves Roche’s Ocrevus (ocrelizumab)—for both PPMS and RMS:

http://finance.yahoo.com/news/fda-approves-genentech-ocrevus-ocrelizumab-003300537.html

Following a three-month extension due of the FDA review for CMC issues (#msg-127314306), the PDUFA date was yesterday.

All signs point to Ocrevus becoming a very big-selling drug.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up